The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Angiotensin II Induces Cardiac Phenotypic Modulation and Remodeling In Vivo in Rats
Abstract
Abstract Cardiac phenotypic modulation and remodeling appear to be involved in the pathophysiology of cardiac hypertrophy and heart failure. We undertook this study to examine whether angiotensin II (Ang II) in vivo, independent of blood pressure, contributes to cardiac phenotypic modulation and remodeling. A low dose (200 ng/kg per minute) of Ang II was continuously infused into rats by osmotic minipump for 24 hours or 3 or 7 days to examine the effects on the expression of cardiac phenotype–related or fibrosis-related genes. This Ang II dose caused a small and gradual increase in blood pressure over 7 days. Left ventricular mRNAs for skeletal α-actin, β-myosin heavy chain, atrial natriuretic polypeptide, and fibronectin were already increased by 6.9-, 1.8-, 4.8-, and 1.5-fold, respectively, after 24 hours of Ang II infusion and by 6.9-, 3.3-, 7.5-, and 2.5-fold, respectively, after 3 days, whereas ventricular α-myosin heavy chain and smooth muscle α-actin mRNAs were not significantly altered by Ang II infusion. Ventricular transforming growth factor-β1 and types I and III collagen mRNA levels did not increase at 24 hours and began to increase by 1.4-, 2.8-, and 2.1-fold, respectively, at 3 days. An increase in left ventricular weight occurred 3 days after Ang II infusion. Treatment with TCV-116 (3 mg/kg per day), a nonpeptide selective angiotensin type 1 receptor antagonist, completely inhibited the above-mentioned Ang II–induced increases in ventricular gene expressions and weight. Hydralazine (10 mg/kg per day), which completely normalized blood pressure, did not block cardiac hypertrophy or increased cardiac gene expressions by Ang II. This study demonstrates that Ang II in vivo, via the type 1 receptor, directly induces a shift to the fetal phenotype of cardiac myocytes and cardiac remodeling independent of blood pressure elevation. Thus, Ang II may play an important role in the modulation of cardiac performance in pathological cardiac hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
Cited by
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
Burstein, B., & Nattel, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.064 · Cited by 1,242
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Self-citationPathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
Extracellular Matrix Remodeling in Heart Failure: A Role for De Novo Angiotensin II Generation
Weber, K. T. (1997) · Circulation · doi:10.1161/01.cir.96.11.4065 · Cited by 557
Khan, R., & Sheppard, R. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02336.x · Cited by 501
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M., Takemoto, Y., Kitakaze, M., & Liao, J. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13350 · Cited by 491
Induction of Cardiac Fibrosis by Transforming Growth Factor-β1
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3032 · Cited by 464
Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice
Dono, R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4213 · Cited by 437
Petrov, V. V., Fagard, R. H., & Lijnen, P. J. (2002) · Hypertension · doi:10.1161/hy0202.103268 · Cited by 419
Paradis, P., Dali-Youcef, N., Paradis, F. W., Thibault, G., & Nemer, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.931 · Cited by 382
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy
Gallo, S., Vitacolonna, A., Bonzano, A., Comoglio, P., & Crepaldi, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092164 · Cited by 264
Brink, M., Wellen, J., & Delafontaine, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118698 · Cited by 262
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy
Nakagami, H. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00145-7 · Cited by 255
Diep, Q. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.11.004 · Cited by 165
A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure
Miner, E. C., & Miller, W. L. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.1.71 · Cited by 86
Metadata
- Authors
- Kim, S., Ohta, K., Hamaguchi, A., Yukimura, T., Miura, K., & Iwao, H.
- Venue
- Hypertension
- Published
- 1995-06
- Volume
- 25
- Issue
- 6
- Pages
- 1252-1259
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2154684959
- Cited by
- 246
- References
- 1
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.